🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

An International Challenge

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million infections each year. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This authorization represents a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Results and Worldwide Availability

As per findings released by a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This places it at an comparable level with the typical regimen, which combines a dual-drug approach. The research enrolled nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have shared optimism. The availability of a one-pill regimen of this kind is hailed as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.